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Background: The belief that all new medicines bring a therapeutic innovation and better health outcomes is
widely shared among the public, health professionals and policy makers.
Objectives: To examine the therapeutic value of new medicines marketed in Australia using two classification systems.
Methods: The therapeutic value of new medicines was categorised using the Motola’s s and the Ahlqvist-Rastad’s
systems for all approvals made by the Australian Therapeutics Goods Administration (TGA) between 2005 and 2007.
Scores were assigned independently by the three authors on the basis of the Public Summary Documents and
Prescrire’ review articles.
Results: Overall, 217 approval recommendations were made including 81 (37.3%) for new indications and 69
(31.8%) for new medicines. In Motola’s rating system, 31 (52.5%) of the 59 drugs were rated as pharmacological or
technological innovations and 28 (47.5%) were rated as therapeutic innovations. Only seven of the 59 drugs (11.9%)
were rated as important innovations. In Ahlqvist-Rastad’s system, only a third of the new drugs were rated as
“added therapeutic value”.
Conclusion: Only a minority of the new medicines marketed in Australia provide added therapeutic value
compared to existing treatments. Stricter regulatory approval criteria would ensure better safety of the public and
simplify the reimbursement processes.
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The definition of what constitutes an innovation varies
depending on the perspective adopted. From an eco-
nomic perspective, pharmaceutical products are consid-
ered innovative as long as they are new and the success
of innovation is defined in terms of sales, with the as-
sumption that higher sales is a measure of the intrinsic
worth of the innovation [1]. Patents are delivered to new
medicines to protect any kind of innovations such as a
novel chemical structure or a new formulation even if it
does not translate into a health benefit [2]. From a pub-
lic health perspective, the value of new medicines lies in
their “therapeutic” value and the health benefits that
they can generate for patients as well as for the society
such as years of life saved, better quality of life or better
tolerance [1].* Correspondence: agnes.vitry@unisa.edu.au
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reproduction in any medium, provided the orA few studies have assessed the therapeutic innovation
of new medicines. In Canada, 68 (5.9%) of the 1147
newly appraised drugs between 1990 and 2003 were
found to be “breakthrough” drugs [3]. In France, the
French independent medical journal, Prescrire has
assessed the therapeutic value of new drugs marketed in
France for almost 30 years. Between 2000 and 2009, of
the 984 new medicines or new indications approved in
France, more than half did not provide anything new [4].
At the European level, only a minority of the 88 biotech-
nological (25%) and 163 non-biotechnological products
(29%) approved by the European Medicines Agency
(EMA) between 1995 to 2004 were categorised as in-
novative [5].
However, the belief that all new medicines bring a
therapeutic innovation and better health outcomes is
widely shared among the public, health professionals
and policy makers [6]. The recognition of the innovation
provided by new medicines was an important issued. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Therapeutic value of new drugs assessed with
Ahlqvist-Rastad’s rating system
Ahlqvist-Rastad’s rating system N %
Drug for conditions with no currently
available treatment
A 0 0.0
Added therapeutic value* B B1 18 30.5
B4 1 1.7
Subtotal 19 32.2
Similar therapeutic value** C C1 5 8.5
C2 20 33.9
Subtotal 25 42.4
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United States (US) Free Trade Agreement (AUSFTA) in
2004 [7,8]. US negotiators were concerned that the pri-
cing policy administered by the Pharmaceutical Benefits
Scheme (PBS) in Australia failed to adequately reward
pharmaceutical innovations [8,9].
The valuation of therapeutic innovation has been
mainly addressed in the context of medicines reimburse-
ment systems but is not a factor taken into consideration
by medicine regulatory agencies. However, classification
systems to categorise the therapeutic value of new medi-
cines have been developed by some medicine agencies
[10] and medical journals including Prescrire in France
[4]. Such classification systems can help informing
health professionals and the public about the real thera-
peutic value of new medicines. They can also be used to
evaluate the new medicines over time and across thera-
peutic categories and to assess the impact of medicine
policies and regulations [3]. The objective of this study
was to examine the therapeutic value of new medicines
marketed in Australia using two classification systems
previously developed.
Methods
The therapeutic value of new medicines was categorised
using two classification systems, the Motola’s system [5]
and the Ahlqvist-Rastad’s system [11]. The Motola’s sys-
tem is currently used by the Italian Medicines Agency
for ranking innovation of new drugs [10]. The degree of
therapeutic innovation is scored by evaluating the
seriousness of the disease, the availability of previous
treatments, and the extent of the therapeutic effect,
according to an algorithm (Table 1) [5]. The medicines
are finally categorised into one of three degrees of thera-
peutic innovation (important, moderate or modest) or a
pharmacological (new mechanism of action) or techno-
logical (new chemical or biotechnological) innovation
without evidence for better efficacy, safety or kinetics than
existing treatments. The Ahlqvist-Rastad’s system was pro-
posed by Prescrire and the Swedish Medical ProductsTable 1 Therapeutic value of new drugs assessed with














Important 7 - - 7 (11.9%)
Moderate 17 - - 17 (28.8%)
Modest 3 1 - 4 (6.8%)
Pharmacological 5 1 - 6 (10.2%)
Technological 22 1 2 25 (42.4%)
TOTAL 54 (91.5%) 3 (5.1%) 2 (3.4%) 59 (100.0%)Agency to classify new medicines into five main categories
with additional subcategories (Table 2) [11].
All recommendations made by the Australian Drug
Evaluation Committee (ADEC) between 2005 and 2007
were accessed from the Therapeutics Goods Administration
(TGA) website (http://www.tga.gov.au/archive/committees-
adec-resolutions.htm) and classified according to type of
approvals and therapeutic class using the Anatomic
Therapeutic Chemical (ATC) classification system. Vac-
cines, diagnostics and desensitising agents were excluded
from the analysis. When new medicines had more than
one indication, therapeutic scores were assigned to each
indication.
The Motola and Ahlqvist-Rastad’s rating scores were
assigned independently by the three authors for all indi-
cations. The sources of information used to inform the
assessment were (1) the Public Summary Documents
(PSDs) summarizing the Australian Pharmaceutical Ben-
efits Advisory Committee (PBAC) assessments of all ap-
plications for funding of new medicines under the
Pharmaceutical Benefits Scheme (PBS) available till No-
vember 2007; (2) the reviews published by Prescrire till
April 2008. These sources were chosen as they are inde-
pendent and provide high quality comprehensive reviews
of the clinical evidence for new medicines. In the few
cases where information was not available from one ofInferior therapeutic value*** D D1 2 3.4
D2 3 5.1
Subtotal 5 8.5
Uncertain therapeutic value**** E 10 16.9
TOTAL 59 100.0
*The effect (B1)/ safety (B2)/ dosage (B3)/ route of administration (B4) seems
to be better for patients than that of previously licensed alternatives.
** First medicine of a new class of agents with similar therapeutic value to
that of previously licensed alternatives (C1).
New agent of an existing class with similar therapeutic value to that of
previously licensed alternatives (C2).
*** First medicine of a new class with inferior therapeutic value to that of
previously licensed alternatives (D1).
New agent of an existing class with inferior therapeutic value to that of
previously licensed alternatives (D2).
****New agent whose therapeutic value remains unknown because evaluation
is limited to its effects on surrogate end points.
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and the European Public Assessment Report (EPAR),
which summarizes the reasons for approval of new drugs
by the European Medicines Agency (EMA), were used.
Disagreements between the 3 authors in assessing medi-
cines were resolved by consensus meetings. Descriptive
comparisons were made between ratings obtained by the
Motola’s system and Ahlqvist-Rastad’s systems. An ana-
lysis of the possible reasons for the differences in ratings
was also undertaken on the basis of the information pro-
vided in the PDSs and Prescrire’s articles.
Results
Figure 1 describes the flow chart of the new drugs / indi-
cations included in the analysis.
Between 2005 and 2007, 217 recommendations were
made by ADEC including 81 (37.3%) recommendations
for new indications, 69 (31.8%) for new drugs. The
remaining was for new forms (11.5%), new dosages
(8.8%), new combinations (7.4%), changes to Product In-
formation (2.3%) and generic products (0.9%). The num-
ber of changes to Product Information and approvals of217 ADEC* 
recommendations 




for new drugs 
55 new drugs 
assessed including 4 
drugs with 2 
indications each 
59 new drugs / 
indications assessed 












Figure 1 Flow chart of the new drugs / indications included in the angenerics were low as most changes to Product Informa-
tion and most approvals of generics do not need to be
reviewed by ADEC. Anti-infectives represented 27.5% of
the new drugs, antineoplastics and immunomoduling
agents 18.8%, drugs for diseases of the alimentary tract
and metabolism 8.7%, drugs for the nervous system
8.7%, drugs for the cardiovascular system 4.8% and drugs
for blood disorders 4.8%.
The assessment of the therapeutic value included 55 out
of the 69 new drugs approved by the ADEC. Fourteen
drugs were excluded from the analysis, including eight
vaccines, four contrast media and two desensitising agents.
As there were four new drugs (dasatinib, posaconazole,
pregabalin and sunitinib) with two different indications, a
total of 59 new drugs/indications were rated for their
therapeutic value.
For 46 (78%) drugs/indications, either the Prescrire’s art-
icle or the Public Summary Documents were available. In
five (8%) cases, the European Product Assessment Reports
(EPAR) was used as there was no Prescrire’s review or Pub-
lic Summary Documents available. In eight (14%) cases, no
information could be retrieved from any of these three148 recommendations excluded 
37.3%) recommendations for new 
ations 
11.5%) recommendations for new forms 
8.8%) recommendations for new 
es 
7.4%) recommendations for new 
inations 
.3%) changes to product information




alysis. * ADEC: Australian Drug Evaluation Committee.
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factor eight inhibitor bypassing fraction, human normal im-
munoglobulin) except one product, butoconazole. The
Product Information was used to rate the therapeutic value
of butoconazole.
Most of the new drugs/indications (91.5%) were indi-
cated for serious diseases such as HIV, hepatitis, cancer,
epilepsy and invasive fungal infections (Table 1). Three
(5.1%) were indicated for the management of risk factors
for serious diseases such as nicotine dependence, osteo-
porosis and hypertension and two (3.4%) for the treat-
ment of non-serious disease such as vulvo-vaginal
candidiasis and urinary incontinence.
In the Motola's system, 31 (52.5%) of the 59 drugs were
rated as pharmacological or technological innovations and
28 (47.5%) were rated as therapeutic innovations (Table 1).
A minority (11.9%) were rated as important innovation.
Most of the biological products were rated as techno-
logical innovation with therapeutic roles similar to the
existing ones.
In the Ahlqvist-Rastad’s system, no drug was approved
for “conditions with no currently available treatment”
(Table 2). Nineteen (32.2%) new drugs were rated as “added
therapeutic value” and 25 (42.4%) as “similar therapeutic
value”. Five (8.5%) were rated as “inferior therapeutic value”
and ten (16.9%) as “uncertain therapeutic value”.
The comparison between the scores obtained with
Motola’s rating system and the Ahlqvist-Rastad’s rating
system showed that all drugs rated as “added therapeutic
value” with the Ahlqvist-Rastad’s system were graded as
important (36.8%), moderate (47.4%) or modest (15.8%)
innovations with Motola’s rating system (Table 3). Most of
the drugs (88.0%) rated as “similar therapeutic value” and
all drugs classified as “inferior therapeutic value” were
graded as pharmacological or technological innovations.
Three drugs (abatacept, fulvestrant and pregabalin) were
rated as “similar therapeutic value” in the Ahlqvist-Rastad’s
system and rated as moderate innovation in the Motola’s
system. The reason is that none of these three medicines
had been shown to have superior efficacy compared toTable 3 Comparison between scores obtained with the Motol
Ahlqvist-Rastad’s rating system




Important 7 (36.8%) -
Moderate 9 (47.4%) 3 (12.0%) *
Modest 3 (15.8%) -
Pharmacological - 2 (8.0%)
Technological - 20 (80.0%)
TOTAL 19 25
* Abatacept, fulvestrant and pregabalin.
** Maraviroc, natalizumab, nitric oxide, pegvisomant and sunitinib.
*** Palifermin.standard treatments. However, they could provide another
therapeutic option for conditions where there were only
limited treatments.
Six drugs (maraviroc, natalizumab, nitric oxide,
pegvisomant, sunitinib and palifermin) were rated as “un-
certain therapeutic value” in the Ahlqvist-Rastad’s system
and rated as therapeutic innovations in the Motola’s sys-
tem. The reasons for the “uncertain” ratings were either
because of the quality of scientific evidence (absence of a
direct comparison with the reference treatment for
natalizumab, use of surrogate outcomes for maraviroc,
maturity of data for sunitinib) or because of safety con-
cerns (risk of progressive multifocal leukoencephalopathy
with natalizumab).
Discussion
The assessment of the therapeutic value of new medi-
cines approved in Australia between 2005 and 2007 in-
cluded a total of 59 new drugs/indications. In Motola’s
rating system, 31 (52.5%) of the 59 drugs were rated as
pharmacological or technological innovations and 28
(47.5%) were rated as therapeutic innovations. Only a
minority (11.9%) were rated as important innovations. In
Ahlqvist-Rastad’s system, only a third of new drugs were
rated as “added therapeutic value”.
Our results are similar to those found in other coun-
tries. In Europe, of 176 medicines approved by EMA be-
tween 1995 and 2004, 49% of the new drugs were
pharmacological or technological innovations and 51%
were therapeutic innovations [5]. Of the 122 medicines
approved by EMA between 1999 and 2005, only 13
(10%) were shown to be superior to already available
medicines in terms of a statistically significant difference
in primary clinical endpoints [12].
Classification using both systems was broadly consist-
ent. The Motola’s system did not include categories for
inferior therapeutic value and uncertain benefits. The
Ahlqvist-Rastad’s system did not include a category for
medicines that could have better efficacy but increased








- 5 (50.0%) ** 17
- 1 (10.0%) *** 4
2 (40.0%) 2 (20.0%) 6
3 (60.0%) 2 (20.0%) 25
5 10 59
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providing an informative summary of the clinical signifi-
cance of new medicines. This may contribute to educate
the public about the real therapeutic value of new medi-
cines and change the beliefs that all new medicines bring
a therapeutic innovation.
The evaluation of the therapeutic value of new medicines
in both systems was complicated by significant scientific
uncertainties. In our study, 17% of the new drugs/indica-
tions were rated as of uncertain therapeutic value. A study
found that more than 40% of all submissions by the Com-
mon Drug Review in Canada and the PBAC in Australia
were associated with considerable clinical uncertainty [13].
Significant uncertainty around comparative clinical efficacy
caused by the use of inappropriate study design, compara-
tors and surrogate end points, was identified as a key issue
in coverage decisions across three national jurisdictions in
Britain, Australia and Canada. The threshold of acceptable
uncertainty is often considered to be higher for new medi-
cines targeting life-threatening diseases. However, even in
this situation, accepting a high level of uncertainty means
that some patients will be exposed to a high risk of severe
adverse effects without gaining any benefit.
The current approval regulations do not require the
demonstration of any improvement in terms of efficacy or
safety for new medicines compared to existing products.
This means that, in practice, medicines with an uncertain
or lower benefit-to-risk ratio can be given the “benefit of
doubt” and be marketed worldwide [14]. Calls have be
made for a strengthening of the criteria for marketing ap-
proval including the requirement to demonstrate at least a
minimal therapeutic improvement, in particular for cancer
drugs [15,16], and requirement of active-controlled trials
[17,18]. Making therapeutic value the criterion for market-
ing authorization may become a realistic option as the role
of third party payers has become more prominent, includ-
ing in Australia where “time-to-market no longer means
time-to-licensing but time-to-reimbursement” [18]. A bet-
ter integration of the functions of regulatory agencies and
health technology assessment bodies would facilitate the
assessment of the therapeutic value of new medicines and
improve the health of the public [17,19].
A limitation of our study is that we assessed the thera-
peutic value of drugs based on data available at the time of
marketing authorisation. However, new evidence may be-
come available after the marketing approval, either as new
evidence of efficacy compared to alternative treatments or
new evidence of efficacy on clinical outcomes rather than
on surrogate outcomes or reporting of new serious ad-
verse effects. This new evidence may change the assess-
ment of the therapeutic value of new drugs, in either a
better or worse direction [20]. A second limitation of this
study is that it is based on publicly available evidence.
At the time of our study, the Therapeutics GoodsAdministration was not publishing any evaluation reports
on newly approved medicines. Since October 2009, the
TGA has been publishing the AusPARs, comprehensive
reports that provide information about the evaluation of
new medicines and the considerations that led the TGA to
approve or not approve an application. However, these re-
ports are long and complex and do not provide an inform-
ative rating of the therapeutic value of new medicines.
Another limitation of this study is the lack of gold stand-
ard methodology for the evaluation of the therapeutic
value of new medicines. Regulatory agencies do no cur-
rently use standardised processes but mostly rely on
expert judgment. A number of quantitative and semi-
quantitative methods designed to weigh all the relevant
efficacy and safety data have been proposed to make more
objective, transparent and consistent decisions [21]. How-
ever, their validity remains to be assessed in the regulatory
context. In our study, we have used independent and
internationally recognised sources of reviews on new med-
icines to inform the value rating in both the Motola’s sys-
tem and Ahlqvist-Rastad’s system.Conclusion
Use of a simple categorisation system could provide a use-
ful, simple and transparent way to better inform the public
and health professionals of the therapeutic value of new
medicines. Currently, only a minority of the new medi-
cines marketed in Australia provide added therapeutic
value compared to existing treatments. By strengthening
approval criteria for new medicines, the Australian gov-
ernment could ensure a better safety of the public and
streamline registration and reimbursement processes.
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